Senti Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SNTI research report →
Range $6 – $6
Price Chart
About the company
Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology. They focus on creating advanced cell and gene therapies that incorporate sophisticated gene circuits, essentially biological computers, to genetically reprogram cells.
- CEO
- Timothy K. Lu
- IPO
- 2021
- Employees
- 39
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on SNTI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $10.31M
- P/E
- -0.19
- Fwd P/E
- 0.59
- PEG
- -0.00
- P/S
- 187.38
- P/B
- -3.03
- EV/EBITDA
- -0.51
- Div Yield
- 0.00%
- Gross Margin
- -2736.36%
- Op Margin
- -102761.82%
- Net Margin
- -90116.36%
- ROE
- -1539.97%
- ROIC
- -227.67%
Latest fiscal year · YoY change
- Revenue
- $22.00K+0.0%
- Gross Profit
- $-3,615,000+0.0%
- Op Income
- $-63,727,000
- Net Income
- $-61,438,000-16.4%
- EPS
- $-2.73+76.2%
- OCF Growth
- -4.9%
- FCF Growth
- -5.4%
- 52W High
- $2.88
- 52W Low
- $0.29
- 50D MA
- $0.35
- 200D MA
- $0.81
- Beta
- 2.22
- RSI (14)
- 47
- Avg Volume
- 567.62K
No earnings-call transcripts are available for SNTI yet.
- Free Float
- 39.4%
- Shares Outstanding
- 31.14M
- Float Shares
- 12.28M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 40.05K | 0 |
| Triatomic Management LP | 15.49K | ▼ 295.04K |
Held by 21 ETFs
Biggest fund positions in SNTI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 9, 26 | Rajangam Kanya | other | 10,757 |
| Mar 9, 26 | Lu Timothy K | other | 80,666 |
| Feb 2, 26 | Rajangam Kanya | other | 1,384 |
| Feb 2, 26 | Lu Timothy K | other | 4,191 |
| Jul 18, 25 | Baum Bryan Daniel | other | 43,900 |
| Jul 18, 25 | Baum Bryan Daniel | other | 0 |
| Jun 25, 25 | Collins James J. | other | 21,950 |
| Jun 25, 25 | Hsiung Feng | other | 21,950 |
| Jun 25, 25 | Schulz Fran | other | 21,950 |
| Jun 25, 25 | COOPERSTONE BRENDA | other | 21,950 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SNTI coverage
Recent articles, reports, and earnings notes.
No research on SNTI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SNTI report →Head-To-Head Analysis: Senti Biosciences (NASDAQ:SNTI) and Celldex Therapeutics (NASDAQ:CLDX)
defenseworld.net · Oct 5
Senti Biosciences (SNTI) to Announce Quarterly Earnings on Thursday
defenseworld.net · Aug 5
Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform
globenewswire.com · Jul 15
Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase
globenewswire.com · May 14
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program
globenewswire.com · May 14
Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026
globenewswire.com · Apr 13
Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies
globenewswire.com · Apr 1
Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
globenewswire.com · Mar 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.